Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
40.6M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
22.4M
-
Shares change
-
+409K
-
Total reported value, excl. options
-
$900M
-
Value change
-
+$13.1M
-
Put/Call ratio
-
0.04
-
Number of buys
-
71
-
Number of sells
-
-47
-
Price
-
$40.18
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q2 2023
145 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q2 2023.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 22.4M shares
of 40.6M outstanding shares and own 55.18% of the company stock.
Largest 10 shareholders include FMR LLC (4.06M shares), BlackRock Inc. (1.74M shares), ALKEON CAPITAL MANAGEMENT LLC (1.68M shares), ORBIMED ADVISORS LLC (1.51M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.27M shares), VANGUARD GROUP INC (1.18M shares), BRAIDWELL LP (1.14M shares), STATE STREET CORP (1.02M shares), Candriam S.C.A. (721K shares), and EVENTIDE ASSET MANAGEMENT, LLC (580K shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.